5/15
08:30 am
veru
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
Low
Report
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
5/14
08:30 am
veru
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
Medium
Report
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
5/14
08:07 am
veru
Veru Inc. (NASDAQ: VERU) is now covered by analysts at B. Riley. They set a "buy" rating and a $5.00 price target on the stock.
Medium
Report
Veru Inc. (NASDAQ: VERU) is now covered by analysts at B. Riley. They set a "buy" rating and a $5.00 price target on the stock.
5/13
08:09 am
veru
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
5/8
06:34 am
veru
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program [Yahoo! Finance]
High
Report
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program [Yahoo! Finance]
5/8
06:30 am
veru
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
High
Report
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
5/6
08:06 am
veru
Veru Inc. (NASDAQ: VERU) had its price target raised by analysts at HC Wainwright from $2.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) had its price target raised by analysts at HC Wainwright from $2.00 to $3.00. They now have a "buy" rating on the stock.
5/2
08:30 am
veru
Veru to Present at the GLP-1 Based Therapeutics Summit
Medium
Report
Veru to Present at the GLP-1 Based Therapeutics Summit
5/1
08:39 am
veru
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 [Yahoo! Finance]
Medium
Report
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 [Yahoo! Finance]
5/1
08:30 am
veru
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
Medium
Report
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
4/30
11:04 am
veru
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
Low
Report
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
4/30
08:48 am
veru
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
Low
Report
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
4/30
08:30 am
veru
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Medium
Report
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
4/29
12:17 pm
veru
World Industry Analysis of Adult Stores, 2014-2023 and 2024-2030: Sex Toys Market Forecast to Account for $34.6 Billion by 2030 [Yahoo! Finance]
Low
Report
World Industry Analysis of Adult Stores, 2014-2023 and 2024-2030: Sex Toys Market Forecast to Account for $34.6 Billion by 2030 [Yahoo! Finance]
4/25
08:33 am
veru
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 [Yahoo! Finance]
Medium
Report
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 [Yahoo! Finance]
4/25
08:30 am
veru
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Medium
Report
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
4/17
01:33 pm
veru
What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]
Medium
Report
What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]
4/15
08:11 am
veru
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.
Low
Report
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.
4/1
04:21 pm
veru
Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]
Low
Report
Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]
4/1
04:05 pm
veru
Veru Announces Date of 2024 Annual Meeting of Shareholders
Low
Report
Veru Announces Date of 2024 Annual Meeting of Shareholders
3/28
08:07 am
veru
Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.
Low
Report
Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.
3/22
04:17 pm
veru
Veru Reschedules Annual Meeting of Shareholders [Yahoo! Finance]
Medium
Report
Veru Reschedules Annual Meeting of Shareholders [Yahoo! Finance]
3/22
04:05 pm
veru
Veru Reschedules Annual Meeting of Shareholders
Medium
Report
Veru Reschedules Annual Meeting of Shareholders
3/12
08:17 am
veru
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
Medium
Report
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss [Yahoo! Finance]
3/12
08:00 am
veru
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Medium
Report
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss